Xencor Inc. (NASDAQ:XNCR) reported an insider transaction earlier this month involving Celia Eckert, the companys senior vice president and general counsel. According to a Form 4 filing with the Securities and Exchange Commission, Eckert sold 1,492 shares of Xencor common stock on March 3, 2026, at a per-share price of $11.8951, producing proceeds of $17,747.
The filing also records activity tied to March 2, 2026. On that date Eckert acquired 18,680 shares of common stock with a stated value of $0, and she was also awarded stock options covering 112,080 shares of Xencor common stock. Those stock options carry an exercise price of $12.30 per share and have an expiration date of March 2, 2036. The option award vests over a four-year schedule - 25% of the options vest on the one-year anniversary of March 2, 2026, with the remaining portion vesting monthly thereafter.
Following the March transactions, Eckert directly holds 81,929 shares of Xencor common stock.
The equity moves come against a backdrop of recent price action and corporate updates. Xencors shares have climbed roughly 49% over the past six months, though the stock was trading at $12.74 at the time of the report and remains about 17% lower year-to-date.
Investor-focused analysis from InvestingPro cited in the filings and related materials characterizes Xencor as trading below its Fair Value estimate. That analysis notes the company carries more cash than debt on its balance sheet but warns that Xencor is quickly burning through cash. The InvestingPro platform is referenced as offering additional ProTips and financial metrics for subscribers.
Corporate developments flagged alongside the insider filing include a change to Xencors royalty arrangement with Alexion Pharmaceuticals. Alexion has informed Xencor that it will stop making royalty payments on U.S. sales of Ultomiris; royalty payments for international sales will continue. In connection with the situation, Xencor obtained a new U.S. patent that extends its royalty term on U.S. sales of Ultomiris until December 2028. The company estimated that the extended U.S. royalty term could generate an incremental $100 million to $120 million in revenue.
On the analyst front, Truist Securities reiterated a Buy rating for Xencor, maintaining a $29.00 price target and pointing to momentum in the TL1A bispecifics area as supportive of the view. Xencor has also outlined corporate priorities and pipeline milestones for 2026, emphasizing its XmAb drug candidates across oncology and autoimmune indications. The company said it expects to present key clinical data during the year for candidates addressing solid tumors and autoimmune conditions.
These combined data points - insider trading, option grants, analyst commentary, royalty and patent developments, and the companys stated clinical timeline - provide multiple inputs that investors and analysts may weigh as they assess Xencors nearer-term prospects and financing profile.